You Searched For: ADIPOGEN CORP MS

Supplier: Adipogen

Description: Peptide antibiotic

Supplier: Adipogen

Description: TNF-related apoptosis-inducing ligand (TRAIL; Apo2L;CD253; TNFSF10) is a type II transmembrane protein of about 34kDa. Like most members of the tumor necrosis factor (TNF) superfamily of cytokines TRAIL can be cleaved at the cell surface by metalloproteases to form a soluble molecule. Active TRAIL forms trimers and specifically binds to five distinct receptors: TRAIL-R1 (DR4; Apo2;CD261; TNFRSF10A), TRAIL-R2 (DR5; KILLER; TRICK2A;TRICK2B; CD262; TNFRSF10B), TRAIL-R3 (DcR1;LIT; TRID; CD263; TNFRSF10C), TRAIL-R4 (DcR2; TRUNDD; CD264; TNFRSF10D), and osteoprotegerin (OPG; OCIF; TNFRSF11B). Trimerized TRAIL triggers apoptosis upon ligation of cell surface TRAIL-R1 and/or TRAIL-R2 by inducing the formation of the so-called multiprotein death-inducing signaling complex (DISC).

Supplier: Adipogen

Description: Angiopoietin-1 (Ang-1) and Angiopoietin-2 (Ang-2) are closely related secreted ligands which bind with similar affinity to Tie-2. Tie-2 and angiopoietins have been shown to play critical roles in embryogenic angiogenesis and in maintaining the integrity of the adult vasculature. Ang-1 activates Tie-2 signaling on endothelial cells to promote chemotaxis, cell survival, cell sprouting, vessel growth and stabilization. Ang-2 has been identified as a secreted protein ligand of Tie-2 and has alternatively been reported to be an antagonist for Ang-1 induced Tie-2 signaling as well as an agonist for Tie-2 signaling, depending on the cell context.

Supplier: Adipogen

Description: NVP-BKM120 is a potent, selective, orally bioavailable Class I PI3Kalpha Inhibitor with IC(50) of 20nM, currently in Phase II clinical trials for the treatment of cancer. It exhibits lower potency against class III and class IV PI3Ks.

Supplier: Adipogen

Description: GSK-25 maintains good selectivity against a panel of 31 kinases, as well as RSK1 and p70S6K (RSK1 IC(50) of 398nM, p70S6K IC(50) of 1000nM), and a dramatically improved P450 profile (<gt/>2.2µM at all isozymes tested).

Supplier: Adipogen

Description: Wide range of tyrosine and serine/threonine protein kinase inhibitor, including Syk, p56lck, PKA, PKC, MLCK, CDPK, JNK and PI3K. Inhibits the tyrosine phosphorylation of STAT3 and STAT5. Potent apoptosis inducer. Potent anticancer compound. Suppresses NF-kB activation through IkBalpha kinase inhibition. Activator of human deacetylase SIRT1 (sirtuin 1). Potent antioxidant with anti-proliferative, anti-inflammatory and cardioprotective properties. Neuoprotective. Adipogenesis inhibitor. Promotes glucose uptake, AMPK phosphorylation and GLUT4 translocation. Autophagy inducer

Supplier: Adipogen

Description: Naturally occurring carnitine derivative formed by carnitine acetyltransferase during beta-oxidation of uneven chain fatty acids, with high affinity for muscular carnitine transferase. Increases cellular carnitine content, allowing free fatty acid transport into the mitochondria. Stimulates energy production in ischaemic muscles by increasing citric acid cycle flux and stimulating pyruvate dehydrogenase activity. Important for mitochondrial metabolism and energy regulation. Regulates the metabolism of both carbohydrates and lipids, leading to an increase of ATP generation. Selectively inhibits in vitro and ex vivo platelet-activating factor (PAF) synthesis from human neutrophils. Antioxidant. Shows free radical scavenging activity. Decreases the expression of inducible nitric oxide synthase (iNOS/NOS II) and NADPH-oxidase 4-mediated reactive oxygen species production in human umbilical vascular endothelial cells. Shows beneficial cardiovascular effects. Improves body weight, food intake, adiposity and insulin resistance in Type 2 diabetes. Stimulates endothelial nitric oxide (eNOS/NOS III) and increased NO production, via AMPK/Src-mediated signaling that leads to activation of PI3 kinase and Akt.

Supplier: Adipogen

Description: Building block for synthesis.

Supplier: Adipogen

Description: (+)-JQ1 is a potent, high affinity, selective BET bromodomain inhibitor (IC(50) values of 17.7, 32.6, 76.9 and 12942nM respectively for BRD2 (N-terminal (N)), BRD4 (C-terminal (C)), BRD4 (N) and CREBBP, respectively. In binding assays, (+)-JQ1 binds competitive with acetyl lysine to BRD4 bromodomain 1 (Kd=50nM) and and BRD4 bromodomain 2 (Kd=90 nM). May be a useful chemical probe to investigate the role of BET bromodomains in the transcriptional regulation of oncogenesis. (+)-JQ1 exhibited strong dose- and time-dependent inhibition of BRDT, a bromodomain-containing protein highly enriched in testis. BRDT is involved in chromatin remodeling and is essential for healthy sperm development. (+)-JQ1 appears to block that function and causes a decrease in sperm viability, being examined as a potential male contraceptive. Inhibitor of inflammation and bone destruction.

Supplier: Adipogen

Description: NVP-BGJ398 inhibits FGFR-WT, FGFR2-WT, FGFR3-K650E, FGFR3-S249C and FGFR4-WT with IC(50) values of 4.6, 4.9, 5, 5 and 168nM, respectively.

Supplier: Adipogen

Description: 5-CFDA is membrane-permeant and can be loaded into cells via incubation. Once inside the cells, 5-CFDA is hydrolyzed by intracellular esterases to 5-carboxyfluorescein. It has been used for labeling human intervertebral disk cells in vitro for fluorescence microscopy. Continuous determination of the intracellular pH in bacteria by fluorometry.

Supplier: Adipogen

Description: A succinimide with anti-epileptic and anti-convulsant properties. The mechanisms of action are unknown and possibly multiple. Metabolically reduced to it's pharmacologically active metabolite N-desmethylmethosuximide.

Supplier: Adipogen

Description: Potent and selective FXR agonist (EC50= 99nM). Induces SHP in HSCs to suppress TIMP-1 expression. Apoptosis inducer. Protects against liver fibrosis development in rat in vivo. Displays anticholeretic activity in rat in vivo. Promotes preadipocyte differentiation. Regulates adipogenesis and insulin signaling in vivo. Inhibits vascular smooth muscle cell inflammation and migration.

Supplier: Adipogen

Description: Potent platinum-based antineoplastic agent with wide spectrum anticancer activity. Anticancer compound. Forms inter- and intrastrand DNA adducts/crosslinks, consequently blocking DNA replication and transcription and inducing cell death. Shows antitumor activity in cisplatin resistant cell lines. Shows better biochemical, pharmacological and cytotoxic properties than cisplatin (Prod. No. AG-CR1-3590) and carboplatin (Prod. No. AG-CR1-3591). Apoptosis inducer. Targets other proteins and enzymes. Anticancer activity and antitumor specificity depends on selective uptake through human organic cation transporters 1 (OCT1) and OCT2. Neurotoxic profile depends on organic cation transporter 2 (OCT2) uptake.

Catalog Number: (102515-624)

Supplier: Adipogen

Description: FasL, Soluble (human) (rec.) induces apoptosis in a concentration range of <1ng/ml in the presence of 0.1 to 1µg/ml of TNF Ligands Enhancer (Prod. No. AG-35B-0001). (Optimal conditions must be determined individually for each cell line tested)

Catalog Number: (102981-536)

Supplier: Adipogen

Description: CD279 (Programmed Cell Death Protein 1; PD-1) is a type I transmembrane protein belonging to the CD28/CTLA-4 family of immunoreceptors that mediate signals for regulating immune responses. Members of the CD28/CTLA-4 family have been shown to either promote T cell activation (CD28 and ICOS) or downregulate T cell activation (CTLA-4 and PD-1). CD279 is expressed on activated T cells, B cells, myeloid cells and on a subset of thymocytes. In vitro, ligation of CD279 inhibits TCR-mediated T cell proliferation and production of IL-1, IL-4, IL-10 and IFN-gamma. In addition, CD279 ligation also inhibits BCR mediated signaling. CD279 deficient mice have a defect in peripheral tolerance and spontaneously develop autoimmune diseases.